Date post: | 07-Aug-2018 |
Category: |
Documents |
Upload: | seprima-yenti |
View: | 222 times |
Download: | 0 times |
of 15
8/20/2019 Chronic Kidney Disease Stage IV
1/35
Case Report
CHRONIC KIDNEY DISEASE
Presenter : Agus Salim (100100027)
Seprima Yenti (100100029)
Supervisor : dr. ell! Rosdiana" Sp.A (#)
INTRODUCTION
C$roni% #idne! &isease (C#&) is a patop$!siologi% pro%ess 'it$ various etiolog! '$i%$
%ause de%rease renal un%tion progressivel!. $is is a %lini%al %ondition '$ere t$e renal
d!sun%tion is irreversi*le and lasting until renal repla%ement t$erap! (dial!sis" renal
transplantation) is needed.1
C#& is a serious pu*li% $ealt$ pro*lem 'it$ national surve!s s$o'ing a %ondirea*l!
gi$ger prevalen%e t$an appre%iated previousl!.2 Re%ent eviden%e indi%ates t$at t$e out%omes %an
*e improved *! earl! diagnosis and treatment.+ ,arlier stages o C#& %an *e dete%ted t$roug$
routine la*orator! measurements. $e presen%e o C#& s$ould *e esta*lis$ed" *ased on presen%e
o -idne! damage and level o -idne! un%tion (glomerular iltration rate /R).
C$ildren '$o $ave C#& ma! present to %lini%ians 'it$ a %om*ination o pro*lemsinvolving gro't$" nutrition" ele%trol!te distur*an%es" renal osteod!strop$!" anemia"
immuni3ations" $!pertension" and renal transplantation. C$ildren 'it$ C#& need a
%ompre$ensive treatment. A team'or- %onsist o pediatri% nep$rologist"nutritionist" psi-ologist
or ps!%$iatri% and patient amil!.4
8/20/2019 Chronic Kidney Disease Stage IV
2/35
EPIDEMIOLOGY
/lo*all!" t$e prevalen%e o %$roni% -idne! disease (C#&) stage 55 or lo'er in %$ildren is
reported to *e appro6imatel! 1.484.+ per million %$ildren. &ata rom t$e 5tal#id stud!
reported a mean in%iden%e o 12.1 %ases per !ear per million in t$e age8related population (age
range" .81+.9 !) and a prevalen%e o 7.7 per million in t$is population. 7 $e reuen%! o
%$roni% -idne! disease in%reases 'it$ age and is mu%$ more %ommon in adults t$an %$ildren.
Among %$ildren" %$roni% -idne! disease is more %ommon in %$ildren older t$an !ears t$an in
t$ose !ounger t$an !ears. $e per%entages in t$e APRCS %o$ort 'ere 19; in %$ildren aged
081 !ears< 17; in t$ose aged 812 !ears< ++; in %$ildren aged 284 !ears< and +1; in t$ose older
t$an 12 !ears.
5n 5ndonesia" t$ere is no prevalen%e o C#& in %$ildren nationall!. =ased on stud! in 7
$ospital in 5ndonesia" 29 %$ildren '$o 'ere treated 'it$ renal disease (!ears 19819)" 2;
o t$em are diagnosed 'it$ C#&.RSC> ?a-arta ound .9; rom o %$ildren '$o are
$ospitali3ed 'it$ -idne! disease are diagnosed 'it$ C#&. $e in%iden%e in t$e /eneral @ospital
&r. Soetomo or 4 !ears (1981992) is 0.07; o all patients $ospitali3ed in t$e pediatri% 'ard.4
DEFINITION AND STAGING
C$roni% -idne! disease (C#&) is t$e presen%e o -idne! damage lasting or at least +
mont$s 'it$ or 'it$out a de%reased /R or an! patient '$o $as a /R o less t$an 0 mBmin
per 1.7+ m2 lasting or + mont$s or more" irrespe%tive o diagnosis (a*el 1).
a*el 1. Criteria or deinition o C#&
A patient $as C#& i eit$er o t$e ollo'ing %riteria are present :
1. #idne! damage or + mont$" as deined *! stru%tural or un%tional a*normalities o t$e
-idne!" 'it$ or 'it$out de%rease /R" maniested *! 1 or more o t$e ollo'ing eatures:
• A*normalities in t$e %omposition o t$e *lood or urine
• A*normalities in imaging tests
• A*normalities on -idne! *iops!
2. /R D0 m.minB1.7+ m2 or + mont$" 'it$ or 'it$out t$e ot$er signs o -idne! damage
des%ri*ed a*ove.
#idne! &isease Eut%omes &isease 5nitiative" 2012. Clinical Practice Guideline for Chronic
Kidney Disease : Evaluation, Clasification and Stratification.
8/20/2019 Chronic Kidney Disease Stage IV
3/35
$e normal level o /R varies a%%ording to age" gender" and *od! si3e. $e normal
/R in !oung adults is 120 to 1+0 mBminB1.7+ m 2" '$ereas t$e normal level o /R is mu%$
lo'er t$an t$is in earl! inan%!" even '$en %orre%ted or *od! sura%e area" and su*seuentl!
in%reases in relations$ip to *od! si3e or up to 2 !ears. Staging o C$roni% #idne! &isease *ased
on #&EF5 is s$o'n in ta*el 2.
a*el 2. #&EF5 Classii%ation o t$e stage o C#&
Stage GFR
(mL/min/1.! m"#
De$%&i'tin A%tin P)an
1 90 #idne! damage 'it$ normal or
in%reased /R
reat primar! and %omor*id %onditions"
slo' C#& progression" CG& ris-
redu%tion
2 089 #idne! damage 'it$ mild
redu%tion o /R
,stimate rate o progression
+ +0849 >oderate redu%tion o /R ,valuate and treat %ompli%ations
14829 Severe redu%tion o /R Prepare or -idne! repla%ement t$erap!
4 D14 ,nd Stage renal ailure #idne! repla%ement t$erap!
#idne! &isease Eut%omes &isease 5nitiative" 2012. Clinical Practice Guideline for Chronic
Kidney Disease : Evaluation, Clasification and Stratification.
ETIOLOGY
C#& $as a prevalen%e o 1.4 to +.0 per 1.000.000 among %$ildren !ounger t$an t$e age
o 1 !ears. 5n %$ildren" C#& ma! *e t$e result o %ongenital" a%uired" in$erited" or meta*oli%
renal disease" and t$e underl!ing %ause %orrelates %losel! 'it$ t$e age o t$e patient at t$e time
'$en t$e C#& is irst dete%ted. C#& in %$ildren D4 !ears old is most %ommonl! a result o
%ongenital a*normalities su%$ as renal $!poplasia" d!splasia" or o*stru%tive uropat$!. Additional
%auses in%lude %ongenital nep$roti% s!ndrome" prune *ell! s!ndrome" %orti%al ne%rosis" o%al
segmental glomerulos%lerosis" pol!%!sti% -idne! disease" renal vein t$rom*osis" and $emol!ti%
uremi% s!ndrome. Ater 4 !ears o age" a%uired diseases (various orms o glomerulonep$ritis
in%luding lupus nep$ritis) and in$erited disorders (amilial Huvenile nep$ronop$t$isis" Alport
8/20/2019 Chronic Kidney Disease Stage IV
4/35
s!ndrome) predominate. C#& related to meta*oli% disorders (%!stinosis" $!pero6aluria) and
%ertain in$erited disorders (pol!%!sti% -idne! disease) %an o%%ur t$roug$out t$e %$ild$ood !ears. 9
Everall" t$e most %ommon %auses o C#& in %$ildren are urologi% a*normalities (+0; to
++;) and glomerulopat$ies (24; to 27;). $ese t'o a*normalities a%%ount or more t$an 40;
o t$e reported %auses o end8stage renal disease in %$ildren. $e ot$er maHor %auses are
$ereditar! nep$ropat$ies (1;) and renal $!poplasia and d!splasia (11;). &ata rom t$e ort$
Ameri%an Pediatri% Renal rial and Colla*orative Studies 200 demonstrate ver! similar
inormation (a*le +).10
a*el +.Common Cause o C$roni% #idne! &isease in C$ildren
Diagn$i$ In%i*en%e
E*stru%tive uropat$! 22;
AplasiaB$!poplasiaBd!splasia 1;
/lomerulonep$ritis 10;
Relu6 nep$ropat$! ;
&il!s A. I$!te and Ri%$ard ine" 200. C$roni% #idne! &isease in C$ildren.
PATOPHYSIOLOGY
Renal un%tion de%rease progressivel! despite t$e primar! disease $as *een resolved or
$ave *e%ome ina%tive. $is %ondition indi%ate a me%$anism o se%ondar! adaptation t$at $as arole in t$e ongoing damage in %$roni% -idne! disease. Ene o t$e eviden%e a*out t$e me%$anism
is t$e presen%e o renal $istologi% eature o C#& t$at %aused *! an! primar! disease. C$ange
and adaptation o t$e remaining nep$ron ollo'ing renal damage in t$e *eginning lead to
ormation o %onne%tive tissue and urt$er damage o t$e surviving nep$rons. $is %ondition 'ill
%ontinue until t$e end stage o renal ailure.11
8/20/2019 Chronic Kidney Disease Stage IV
5/35
igure 1. C!%le o t$e %$roni% -idne! disease
Iassner S?" =aum > (1999). C$roni% Renal ailure. P$!siolog! and >anagement. 5n: =arrat
>" Avner ,&" @armon I," ,ditors. Pediatri% ep$rolog!" t$ edition. =altimore: ippin%ott
Iilliams J Iil-ins" pp. 11448112.
@!periltration inHur! ma! *e an important inal %ommonpat$'a! o glomerular
destru%tion" independent o t$e underl!ing %ause o renal inHur!. As nep$rons are lost" t$e
remaining nep$rons undergo stru%tural and un%tional $!pertrop$! %$ara%teri3ed *! an in%rease
in glomerular *lood lo'. $e driving or%e or glomerular iltration is t$ere*! in%reased in t$e
surviving nep$rons. Alt$oug$ t$is %ompensator! $!periltration temporaril! preserves total renal
un%tion" it %an %ause progressive damage to t$e surviving glomeruli" possi*l! *! a dire%t ee%t
o t$e elevated $!drostati% pressure on t$e integrit! o t$e %apillar! 'all andBor t$e to6i% ee%t o
in%reased protein trai% a%ross t$e %apillar! 'all. Ever time" as t$e population o s%lerosed
nep$rons in%reases" t$e surviving nep$rons suer an in%reased e6%retor! *urden" resulting in a
vi%ious %!%le o in%reasing glomerular *lood lo' and $!periltration inHur!.9
8/20/2019 Chronic Kidney Disease Stage IV
6/35
Proteinuria itsel %an %ontri*ute to renal un%tional de%line" as eviden%ed *! studies t$at
$ave s$o'n a *enei%ial ee%t o redu%tion in proteinuria. Proteins t$at traverse t$e glomerular
%apillar! 'all %an e6ert a dire%t to6i% ee%t on tu*ular %ells and re%ruit mono%!tes and
ma%rop$ages" en$an%ing t$e pro%ess o glomerular s%lerosis and tu*ulointerstitial i*rosis.
Kn%ontrolled %an $!pertension e6a%er*ate disease progression *! %ausing arteriolar
nep$ros%lerosis and *! in%reasing t$e $!periltration inHur!. @!perp$osp$atemia %an in%rease
progression o disease *! leading to %al%ium p$osp$ate deposition in t$e renal interstitium and
*lood vessels. @!perlipidemia" a %ommon %ondition in C#& patients" %an adversel! ae%t
glomerular un%tion t$roug$ o6idant8mediated inHur!.9
CLINICAL MANIFESTATION
,arl! %lini%al maniestation o C#& doesnLt s$o' spe%ii% s!mptoms su%$ as di33iness"
letargis" anore6ia" nausea.4 C#& patient rom %$roni% glomerulonep$ritis %an present 'it$
edema" $!pertension" $ematuria" and proteinuria. 5nants and %$ildren 'it$ %ongenital disorders
su%$ as renal d!splasia and o*stru%tive uropat$! %an present in t$e neonatal period 'it$ ailure to
t$rive" pol!uria de$!dration" urinar! tra%t ine%tion" or overt renal insui%ien%!. Congenital
-idne! disease is diagnosed 'it$ prenatal ultrasonograp$! in man! inants" allo'ing earl!
diagnosti% and t$erapeuti% intervention. C$ildren 'it$ amilial Huvenile nep$ronop$t$isis %an
$ave a ver! su*tle presentation 'it$ nonspe%ii% %omplaints su%$ as $eada%$e" atigue" let$arg!"
anore6ia" vomiting" pol!dipsia" pol!uria" and gro't$ ailure over a num*er o !ears. 9
5n p$!si%al e6amination 'e ound a pallor" limp" and $!pertension. $e %ondition last or
along time and more da! more severe. Kremia is a to6i% s!ndrome %aused *! severe glomerular
damage" tu*ular d!sun%tion" and renal endo%rine un%tion.4
Clini%al maniestation is t$e result o :
1. luid and ele%trol!te im*alan%e
2. overa%umulation o uremi% to6in.
+. @ormonal d!sun%tion (de%rease o er!tropoeitin and vitamin &+)
. unresponse o end organ 'it$ gro't$ $ormone.
8/20/2019 Chronic Kidney Disease Stage IV
7/35
LA+ORATORY FINDING
a*orator! indings %ould *e ound :9
1. %omplete *lood %ount normo%$romi%" normo%!ti% anemia.
2. Renal un%tion est serum ureum and %reatinine.
+. ,le%trolite $!per-alemia" $!ponatremia (i volume overloaded)" a%idosis"
$!po%al%emia" $!perp$osp$atemia.
. Krinalisis proteinuria and $ematuria i %aused *! glomerulonep$ritis in $eav!
proteinuria %ould *e ound $!poal*uminemia.
/lomerular iltration rate (/R) used or staging o C#&. 5n %$ildren" t$e ormula to
estimate patientLs /R are s$o'n *elo' :12
I$ere k is :
1. 0.++ or lo'8*ir$t'ei$t inant D1 !ear old
2. 0.4 or term inant D1 !ear old '$ose 'eig$t is appropriate or gestational age
+. 0.44 or %$ildren (181+ !ears old)
. 0.47 or adoles%ent girls (1+821 !ears old)
4. 0.70 or adoles%ent *o!s (1+821 !ears old)
TREATMENT
Patients 'it$ C#& s$ould *e evaluated to determine:
1. &iagnosis (t!pe o -idne! disease)
2. Comor*id %onditions (su%$ as $!perlipidemia)
+. Severit!" assessed *! level o -idne! un%tion
. Compli%ations" related to level o -idne! un%tion
4. Ris- or loss o -idne! un%tion. Ris- or %ardiovas%ular disease
reatment o C#& s$ould in%lude:
1. Spe%ii% t$erap!" *ased on diagnosis
2. ,valuation and management o %omor*id %onditions
8/20/2019 Chronic Kidney Disease Stage IV
8/35
+. Slo'ing t$e loss o -idne! un%tion
. Prevention and treatment o %ardiovas%ular disease
4. Prevention and treatment o %ompli%ations o de%reased -idne! un%tion (eg"
$!pertension" anemia" a%idosis" gro't$ ailure)
. Preparation or -idne! ailure t$erap!
7. Repla%ement o -idne! un%tion *! dial!sis and transplantation"
i signs and s!mptoms o uremia are present" a %lini%al a%tion plan s$ould *e developed
or ea%$.
1. N,t&itin
C$ildren '$o $ave C#& $ave nutrition and protein dei%ien%ies or several reasons"
in%luding anore6ia" nausea and vomiting rom t$e uremia" and an a*normal sense o taste. Young
%$ildren" in parti%ular" need sui%ient %alori% inta-e to gro'. Protein inta-e s$ould *e optimi3ed
to allo' or maintenan%e o nitrogen *alan%e and preservation o lean *od! mass. Some patients
ma! reuire supplemental nasogastri% or gastrotom! tu*eeeding i t$e! %annot maintain optimal
$eig$t and 'eig$t gain *! oral eeding. @o'ever" i protein inta-e ise6%essive" $!periltration
ma! o%%ur" leading to in%reased damage to t$e renal paren%$!ma. >i%ropun%ture studies
demonstrate an in%rease in t$e /R ($!periltration) ater an amino a%id load due to redu%tion in
aerent arteriolar resistan%e.
Prostaglandins" '$i%$ %an alter vas%ular tone and in%rease t$e /R" re%entl! $ave *een
impli%ated in t$e development o $!periltration *e%ause prostaglandin values $ave *een noted to
in%rease in response to an in%reased amino a%id load. Protein restri%tion 'as *elieved to slo' t$e
progression o renal disease" *ut t$is ee%t $as not *een veriied in %$ildren. Redu%ing protein
inta-e to 0. to 1.1 gB-g per da! $as not *een s$o'n to ae%t linear gro't$ negativel!. =e%ause
man! vitamins are lost during dial!sis" pediatri% patients undergoing t$is t$erap! s$ould
supplement t$eir diets 'it$ vitamins" espe%iall! oli% a%id" tra%e minerals" and = %omple6es.
Spe%iali3ed ormulas t$at $ave $ig$ energ! %ontents and lo'er ele%trol!te %ontents $ave
*een developed or inants and %$ildren '$o $ave C#&. $ese are reasona*le ormulas or an
older %$ild alread! on dial!sis '$o ma! *e not *e meeting $is or $er nutritional goal or '$o is
e6perien%ing poor 'eig$t gain or gro't$.
8/20/2019 Chronic Kidney Disease Stage IV
9/35
". F),i* an* E)e%t&)ite Im-a)an%e
@!per-alemia is a %ompli%ation o C#&. 5n t$e $ealt$! -idne!" potassium rea*sorption
o%%urs in t$e pro6imal tu*ules and t$e loop o @enle" and se%retion o up to 90; o t$e dail!
inta-e o potassium o%%urs in t$e distal tu*ules. As renal disease progresses" t$e distal tu*ules o
t$e remaining nep$rons %ontinue to se%rete potassium. 5n%reased aldosterone also en$an%es
potassium se%retion *! stimulating sodium8potassium e6%$ange in t$e -idne!s and t$e %olon.
@o'ever" $!per-alemia develops rom an in%rease in dietar! potassium t$at over'$elms t$e
%ompensator! me%$anisms or *! use o medi%ations t$at alter potassium se%retion
(spironola%tone" amiloride" or angiotensin %onverting en3!me in$i*itors). a*le lists
approa%$es to treating $!per-alemia. @!po-alemia also %an o%%ur in %$ildren '$o $ave C#& *ut
tends to develop in patients '$o $ave tu*ular dee%ts su%$ as seen 'it$ an%oni s!ndrome.
a*el . reatment o $!per-alemia
Produ%t &ose Potential adverse ee%ts
Sodium *i%ar*onate (0. M == M *i%ar*onate
desired8*i%ar*onated o*served) B2
0.481 m,B-g 5G over 1 $our
@!po%al%emia
Cal%ium glu%onate (10;) 0.481 mB-g 5G over 4814 min Arr$!t$mia
/lu%ose and insulin /lu%ose 0.4 gB-g 'it$ insulin 0.1
unitB-g 5G over +0 min
@!pogl!%emia
Sodium pol!st!rene
sulonate
1gB-g per dose PR or PE ConstipationBdiarr$ea
=eta agonist 4810 mg aerosoli3ed a%$!%ardia" $!pertension
5GN intravenous" PEN orall!" PRNre%tall!
&il!s A. I$!te and Ri%$ard ine" 200. C$roni% #idne! &isease in C$ildren.
!. A%i*-a$e im-a)an%e
>eta*oli% a%idosis develops in patients '$o $ave C#& *e%ause o a*normall! de%reased
*i%ar*onate rea*sorption o iltered *i%ar*onate" redu%tion o renal ammonia s!nt$esis" de%reased
a%idiied tu*ular luid" and de%reased titrata*le a%id e6%retion. &e%line in /R *elo' 40; o
8/20/2019 Chronic Kidney Disease Stage IV
10/35
normal is a%%ompanied *! a de%line in *i%ar*onate rea*sorption. Redu%ed *i%ar*onate
rea*sorption leads to s!stemi% a%idosis" '$i%$ %auses protein degradation and elu6 o %al%ium
rom *one. Su%$ a%tors pla! a role in t$e poor linear gro't$ o*served in %$ildren '$o $ave
C#&.
$erap! s$ould target maintaining a serum *i%ar*onate %on%entration o 20 to 22 m,B
(20 to 22 mmolB). =i%ar*onate repla%ement %onsists o administering sodium *i%ar*onate
supplements or p$osp$ate *inders. >ost availa*le *inders $ave a *ase %omponent su%$ as
%al%ium %ar*onate.
. H0'e&ten$in
@!pertension is diagnosed in %$ildren '$o $ave C#& *! inding an elevated *lood
pressure reading on t$ree or more separate oi%e visits at least 1 'ee- apart. $e diagnosis is
*ased on t$e %$ildLs age" se6" and $eig$t per%entile. /rades o $!pertension are as ollo's" *ased
on ta*les or grap$s o normal values:
Pre$!pertension: Average s!stoli% or diastoli% pressuresare at t$e 90t$ per%entile or
greater *ut at or less t$an t$e 94t$ per%entile or age" se6" and $eig$t
Stage 5 $!pertension: Average s!stoli% or diastoli% pressure is at or greater t$an t$e
94t$ per%entile or age" se6" and $eig$t
Stage 55 $!pertension: Average s!stoli% or diastoli% pressure is more t$an 4mm@g
$ig$er t$an t$e 94t$ per%entile
@!pertensive urgen%! and emergen%!: Average s!stoli% or diastoli% pressure is more
t$an 4 mm @g $ig$er t$an t$e 94t$ per%entile and %lini%al s!mptoms o $eada%$e"
vomiting" sei3ures" or en%ep$alopat$! are present
5n addition to determining t$e underl!ing %ause o t$e $!pertension" %lini%ians s$ould
monitor patients at least annuall! 'it$ e%$o%ardiograp$! to assess un%tion and let ventri%ular
status. >edi%ations are adHusted to improve %ardia% un%tion. $ose %$ildren '$o all into t$e
$!pertensive urgen%! and emergen%! %ategor! reuire intravenous medi%ations or a rapid8a%ting
oral medi%ation (niedipine or mino6idil) to redu%e *lood pressure.
8/20/2019 Chronic Kidney Disease Stage IV
11/35
. Anemia
Anemia in C#& is %aused *! eit$er an insui%ient produ%tion o er!t$ropoietin *! t$e
diseased -idne!s or *! iron dei%ien%!. Anemia is deined as a redu%tion in red *lood %ell volume
or $emoglo*in %on%entration *elo' t$e normal range or a $ealt$! person. >or*idit!" mortalit!"
and ualit! o lie data rom t$e #&EF5 guidelines suggest t$at maintaining t$e $emato%rit in
t$e range o ++; to +; (0.++ to 0.+) and t$e $emoglo*in at 11.0 to 12.0 gBd (110.0 to 120.0
gB) is important or %$ildren '$o $ave C#&. Prior to t$e development o re%om*inant $uman
er!t$ropoietin" patients '$o $ad C#& $ad to undergo transusions to in%rease t$eir $emato%rit
values. ransusions not onl! e6posed patients to various ine%tious agents *ut e6posed and
sensiti3ed t$em to $uman l!mp$o%!te antigens" putting t$em at in%reased ris- or reHe%tion
s$ould t$e! undergo renal transplantation.
Iit$ improvement o anemia" %$ildren demonstrate improvement in %ognitive
development" %ardia% un%tion" and e6er%ise toleran%e" as 'ell as de%reased mortalit!. As stated"
anemia is %aused *! eit$er an insui%ient produ%tion o er!t$ropoietin *! t$e diseased -idne!s or
*! iron dei%ien%!. &ue to de%reased appetites" %$ildren '$o $ave C#& %annot in%rease t$eir
iron stores adeuatel! t$roug$ an oral diet. Eral iron t$erap! s$ould *e administered at a dose o
2 to + mgB-g per da! o elemental iron in t'o or t$ree divided doses. 5ron s$ould *e %onsumed
on an empt! stoma%$ and not %on%omitantl! 'it$ p$osp$ate *inders *e%ause iron *inds to t$e
p$osp$ate *inders.
Parenteral iron %an *e provided to t$ose '$o %ontinue to lose *lood or '$o %annot
tolerate oral iron. Parenteral iron %an *e administered easil! to patients re%eiving $emodial!sis
*e%ause t$e! alread! $ave vas%ular a%%ess. 5ntravenous iron also %an *e used or t$e peritoneal
dial!sis patient '$o is resistant to oral iron or is non%ompliant in ta-ing oral iron.
,r!t$ropoietin %an *e administered su*%utaneousl! to %$ildren '$o $ave C#&" in%luding
t$ose undergoing peritoneal dial!sis" or intravenousl! or t$ose re%eiving $emodial!sis.
,r!t$ropoietin %an *e given one" t'o" or t$ree times per 'ee-. $e initial dose ranges *et'een
+0 and +00 unitsB-g per 'ee-" 'it$ t$e usual maintenan%e dosage *et'een 0 and 00 unitsB-g
per 'ee-. $e maintenan%e dose is determined and adHusted *ased on mont$l! $emoglo*in
values. A ne' orm o er!t$ropoietin" dar*epoetin ala" '$i%$ $as a longer $al8lie and reuires
dosing on%e ever! 2 'ee-s to on%e mont$l!" is *eing investigated or use in %$ildren.
8/20/2019 Chronic Kidney Disease Stage IV
12/35
2. G&3t4
/ro't$ retardation is one o t$e maHor %ompli%ations o a %$ild '$o $as C#&. $e
degree o gro't$ ailure $as *een %orrelated 'it$ age o onset o C#&.
$e %ause o gro't$ ailure is *elieved to *e multia%torial" in%luding :
gro't$ $ormone (/@) and insulin8li-e gro't$ a%tor85 (5/85) un%tion
nutritional status
a%id8*ase *alan%e
*one minerali3ation.
I$en renal un%tion is redu%ed" /@ is in%reased *e%ause o de%reased %learan%e *! t$e
-idne!s despite t$e normal pulsatile release o t$e $ormone" '$i%$ %ontinues despite t$e
in%reased /@ %on%entrations. Resistan%e to /@ and to 5/85 also is *elieved to lead to gro't$
redu%tion. 5n some studies" serum /@ %on%entrations are in%reased in patients '$o $ave C#&"
*ut t$e %on%entrations o /@ re%eptors are redu%ed. Anot$er %ause ma! *e t$e upregulation o
intra%ellular in$i*itors" la*eled suppressors o %!to-ine signaling (SECS). $e SECS proteins
%an alter t$e p$osp$or!lation o /@ re%eptors and ma! %ause /@ resistan%e.
Similarl!" 5/81 resistan%e pro*a*l! is due to several %auses. 5/8*inding proteins" o
'$i%$ si6 are no' identiied" in%rease 'it$ renal ailure and most li-el! in$i*it t$e a%tions o
5/81 *! *inding 'it$ it" t$ere*! preventing 5/81 rom *inding to its re%eptor. Et$er $ormones
t$at pla! a role in pu*ertal gro't$ and development $ave *een ound to *e redu%ed in %$ildren
'$o $ave C#&" in%luding luteini3ing $ormone" plasma testosterone" and ree testosterone.
reatment o gro't$ ailure initiall! involves resolving nutritional dei%ien%ies and
improving t$e a%id8*ase *alan%e o %$ildren '$o $ave C#&. En%e t$ese tas-s are a%%omplis$ed"
ae%ted %$ildren *egin /@ t$erap! i gro't$ retardation persists. >ost patients '$o $ave C#&
gro' '$en given t$e re%ommended starting dose o 0.04 mgB-g per da!" administered
su*%utaneousl! dail!. I$et$er patients in t$e pu*ertal age group reuire additional /@ needs
additional investigation.
8/20/2019 Chronic Kidney Disease Stage IV
13/35
PROGNOSIS
A*out 70; o %$ildren 'it$ %$roni% -idne! disease develop ,SR& *! age 20 !ears.
C$ildren 'it$ ,SR& $ave a 108!ear survival rate o a*out 0; and an age8spe%ii% mortalit! rate
o a*out +0 times t$at seen in %$ildren 'it$out ,SR&. $e most %ommon %ause o deat$ in t$ese
%$ildren is %ardiovas%ular disease" ollo'ed *! ine%tion. E t$e deat$s due to %ardiovas%ular
%auses" 24; 'ere attri*uted to %ardia% arrest (%ause un%ertain)" 1; to stro-e" 1; to
m!o%ardial is%$emia" 12; to pulmonar! edema" 11; to $!per-alemia" and 22; to ot$er
%ardiovas%ular %auses" in%luding arr$!t$mia. =ut %urrentl!" survival rate o %$ildren 'it$ C#& is
more *etter. &ata rom t$e Australia and e' Oealand (AO) registr! revealed t$at t$e ris- o
deat$ 'as asso%iated 'it$ t$e !ear in '$i%$ renal repla%ement t$erap! 'as initiated" t$e age o
patients at t$e start o t$at t$erap!" and t$e t!pe o dial!sis used.11
8/20/2019 Chronic Kidney Disease Stage IV
14/35
CASE REPORT
ame : .A.O
Age : 14 a$un
Se6 : >ale
&ate o Admission : August" 12t$ 201
C4ie5 Cm')aint : oss o %ons%iousness
Hi$t&0:
$is $as *een $appened *! t$e patient da!s ago. Patient didnQt respond '$en amil! as-ing
or %onversation. Patient *e more uite even t$e patient spo-e" t$at 'as in%o$erent. Patient is a
oldterm patient in nep$rolog! division pediaetri% departemen. ast mont$" t$e patient 'as
re%ommended or $ospitali3ation" *ut t$e patient reused.
@istor! o vomit suered *! patient + da!" reuen%! ive times per da!" volume spoon.$e %ontent is '$at patient eat and drin-. o'" t$e vomit 'as denied.
&iare 'asnQt ound. last dee%ation t$ree da!s ago. @istor! o pale ae%es 'as denied. ast
urination 2 da!s ago. @istor! o urine li-e a tea 'as denied.
ever 'asnQt ound" $istor! o ever also denied
@istor! o sei3ure 'as ound ive mont$s ago" reuen%! on%e a da!. As soon as t$e patient
$ospitali3ed at RSKP @A>.
@istor! o 'eig$t loss 'as ound" $istor! o appetite loss 'as ound
Hi$t&0 5 '&e6i,$ i))ne$$ : 8
Hi$t&0 5 *&,g$ 7 Spironola-ton" urosemide
P40$i%a) E8aminatinGeneralized status
=od! 'eig$t: 0 -g" =od! lengt$: 14 %m
=od! 'eig$t a%%ording to age : 0B4 N 71;
=od! $eig$t a%%ording to age : 14B170 N97;
=od! 'eig$t a%%ording to *od! $eig$t : 0B41 N 7;
5nterpretation : Kndernutrition
Presens status
Cons%iousness: /CS : 1+ (,G>4)" =lood pressure 10B100 mm@g" @R: 9 *pm" RR: 2 *pm"
*od! temperature: +"oC" *od! 'eig$t : 0 -g" *od! $eig$t : 14 %m
Anemi% ()< 5%teri% (8)< C!anosis (8)< ,dema (8). &!spnea (8).
Localized status
Head :
,!e: iso%$ori% pupil (+mmB+mm)" lig$t rele6 (B) " %onHun%tiva palpe*ral inerior pale (B)"
i%teri% s%lera (8).
8/20/2019 Chronic Kidney Disease Stage IV
15/35
ose: nasal septum : no deviation" mu%osa %olor dar- pin-" pol!ps (8)" sinus tenderness (8)"
dis%$arge (8).
,ar : ,6ternal auditor! %anal: no dis%$arge" t!mpani% mem*rant: inta%t" no inlammation"
>out$: lips : %olor is red" issures< =u%al : dar- pin-" glistening< tounge : dar- pin-" papilla
at$rop! (8)" tremor (8)
eet$ and gums : t'ent! teet$" %aries (8).
onsil : dii%ult to assess
Neck :
!mp$ node enlargement (8)" e%- rigidit! (8)
Thora:
5nspe%tion : S!mmetri%al usiormis" epigastrial retra%tion (8)" RR: 20 6Bi" reguler
Palpation : S rig$t N let" normal
Per%ussion : Sonor
Aus%ultation : rales (8B8) " stridor (8B8).
!"do#en:
5nspe%tion : S!mmetri%al usiormis
Palpation : Soepel" iver and spleen unpalpa*le
Per%ussion : !mpani
Aus%ultation : ormoperistalti%
Etre#ities:
,6tremitas superior : Pulse 9 *pm" regular" adeuate pressure and volume" 'arm"
CR D +" spasti% (8B8).
,6tremitas inerior : Pulse 9 *pm" regular" adeuate pressure per volume" 'arm"
CR D +" spasti% (8B8).
$ro%enital :
>ale" 'it$in normal limit.
8/20/2019 Chronic Kidney Disease Stage IV
16/35
La-&at&0 Fin*ing$ (A,g,$t 1"t4 "91# 7
Parameters Galue ormal Galue
Co#&lete 'lood Count
Hemg)-in ."9 g&: 1!." ; 1.! g&:
Hemat%&ite 1.9 : ! ; < :
E&it4&%0te ".! 8 19
2
/mm
!
."9 ; .= 8 19
2
/mm
!
eu%o%!te 11.+7 6 10+ Bmm+ .4 T 11 6 10+Bmm+
Platelet 20.000 Bmm+ 140 8 40Bmm+
MC> !.9 5) = ; C@ +0.0 pg 2 8 +2 pg
>C@C 1.0 gr; ++ 8 +4 gr;
R&I 1+.20 ; 11. T 1. ;
>PG .00 l 7.0 T 10.2 l
PC 0.+;
P&I 7.;
@itung ?enis
eutroil.90;
+780
imosit9.70;
2080
>onosit+.+0;
28
,osinoil0.10;
18
=asoil0.000;
081
eutroil a*solute9.
1"984"
imosit a*solute1.10
+"7810"7
>onosit a*solute 0.+ 0"+80"
,osinoil a*solute 0.01 0"280"4
=asoil a*solute0.00
080"1
Parameters Galue ormal Galue
Ana)i$a Ga$ Da&a4
p@ 7.+1 7.+4 T 7.4
PCE2 27.9 mm@g + T 2
PE2 141.7 mm@g 4 T 100
=i-ar*onat 29.4 mmolB 22 T 2otal CE2 14.1 mmolB 19 T 24
#ele*i$an =asa (=,) 84.0 mmoB (82) T (2)
Saturasi E2 99.+; 94 T 100
Car"ohydrate (eta"olis#
=lood /lu%ose ad random 19.00 mgBd D 200
)enal *unction Test
8/20/2019 Chronic Kidney Disease Stage IV
17/35
U&e,m 1=.99 mg/*L ? 9
C&eatinine .
8/20/2019 Chronic Kidney Disease Stage IV
18/35
Management7@
E6!gen 1 T 2 Bi nasal %anule ()" nasogastri% tu*e (8)
5G& &4; 4 gttBi
Spironola-ton 2 6 24 mg&iet pediasure mil- &iet 1994 --al 0 g protein
Diagn$ti% P)anning7
C$est M8ra!
Complete *lood %ount
/lu%ose ad random
,le%trol!te (a" #" Cl)
=lood gas anal!sis
Krin anal!sis
ep$rolog! %onsult
KS/ &oppler E #idne! and =ladder
8/20/2019 Chronic Kidney Disease Stage IV
19/35
F))3 U' Patient$
A,g,$t@ 1" t4 "91
S oss o %ons%iousness
O Sens: /CS 1 " emp: +.oC. Anemi% (). 5%teri% (8). ,dema (8). C!anosis (8) &!spnoe
(8)
=od! 'eig$t: 0 -g" =od! lengt$: 14 %m
@ead Rig$t ,!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().
et e!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ()..
e%- !mp$ node enlargement (8)$ora6 Simetris usiormis. Retra%tion (8) epigastrial< inter%ostals" suprasternal.
@R: 9 *pm" reguler< murmur (8)
RR: 2 6Bi" regular" rales (8)
A*domen Soepel" Rapid turgor. normoperistalti%. iver" spleen and renal
unpalpa*le.
,6tremities Pulse 9 6Bi" regular" adeuate pBv" 'arm" CR D +U. =lood Pressure
10B100 mm$g
/enital >ale< 'it$in normal limit.
A C$roni% #idne! &isease Stage 5G
P Management7
E2 182 Bi5G& &4; 4 gttB5 mi-ro
Spironola-ton 2624 mg
&iet >il- Pediasure &iet 1994 --al +2 g protein@iponatremia %orre%tion
ast Corre%tion N (12089) 6 0 6 0. N 401. m, (inis$ed in $ours. Iit$ aCl
+; N 401.B41+ N977%% N 10 gttB5 mi%ro
Slo' %orre%tion N (1+48124) 6 0 6 0. N 20 m,B
>aintanan%e N 2 8 m,B N 0 T 10 m,Botal N +20 T 00 m,
Iit$ 5G& &4; aCl 0.9; N +20B14 6 1000 N 2077 %% 144 gttB5 mi%ro"
inis$ed in 1 $ours
@ipo%alemia %orre%tion
1.7 m,B 'it$ 0.74 m,B-g==" +0 m, #Cl in 90 %% &4;" inis$ed in + $ours N
0 gttB5 mi%ro
Planning :,le%trolit test repetition post %orre%tion" ull *lood" and A/&
&ipsti%- result
KroB=ilB#etB=loodBProBitBeuB/[email protected]
A,g,$t 1!t4 "91
8/20/2019 Chronic Kidney Disease Stage IV
20/35
S limp ()" nausea and vomit (8)" ever (8)
O Alert : Compos >entis " emp: +"7oC. Anemi% (). 5%teri% (8). ,dema (8). C!anosis (8)
&!spnoe (8)
=od! 'eig$t: 0 -g" =od! lengt$: 14 %m
@ead Rig$t ,!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().
et e!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ()..
e%- !mp$ node enlargement (8)$ora6 Simetris usiormis. Retra%tion (8) epigastrial< inter%ostals" suprasternal.
@R: *pm" reguler< murmur (8)
RR: 2 6Bi" regular" rales (8)
A*domen Soupel" Rapid turgor. normoperistalti%. iver" spleen and renal
unpalpa*le.
,6tremities Pulse 6Bi" regular" adeuate pBv" 'arm" CR D +U. =lood Pressure
10B100 mm$g/enital >ale< 'it$in normal limit.
A C$roni% #idne! &isease Stage 5G
P E2 182 B5
5G& &4; 4 gttB5 mi-ro
Spironola-ton 2624 mg
&iet 1994 --al protein +2 gram
Planning :
,le%trolit and A/&A repetition test ( i %orre%tion o $ipo%alemia and $iponatremia
inis$ed).Iater =alan%e
5nput :&iet N 1.400 %% Eutput : EKP N 900 %% = N 5 8 E
5G& N +0 %% =A= N 0 N + %%
otal N 1.42 %% 5I N 190 %% #?= N @S =C
otal N 1.090 %% N 1010 %%
A,g,$t@ 1t4 "91
S limp ()" nausea and vomit (8)"ever (8)
E Alert : Compos >entis " emp: +"oC. Anemi% (). 5%teri% (8). ,dema (8). C!anosis (8)
&!spnoe (8)
=od! 'eig$t: 0 -g" =od! lengt$: 14 %m@ead Rig$t ,!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().
et e!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().. e%- !mp$ node enlargement (8)
$ora6 Simetris usiormis. Retra%tion (8) epigastrial< inter%ostals" suprasternal.
8/20/2019 Chronic Kidney Disease Stage IV
21/35
@R: 9 *pm" reguler< murmur (8)
RR: 2 6Bi" regular" rales (8)
A*domen Soupel" Rapid turgor. normoperistalti%. iver" spleen and renal
unpalpa*le.
,6tremities Pulse 9 6Bi" regular" adeuate pBv" 'arm" CR D +U. =lood Pressure
1+0B90 mm$g/enital >ale< 'it$in normal limit.
A C$roni% #idne! &isease Stage 5G
P Management7
E2 V 8 1 B5 nasal -anul
5G& &4; 4 gttB5 mi%ro
Spironola-ton 2624 mg
&iet pediasure mil- &iet 1994 --al +2 g protein
Iater =alan%e
5nput : &iet N 00 %% Eutput : EKP N 00 %% = N 5 8 E
5G& N 140 %% =A= N 0 N 80%%
otal N 740 %% 5I N 190 %% #?= N @S =C
otal N 790 %% N ++4 %%
A,g,$t@ 1t4 "91
S limp ()" nausea and vomit (8)"ever (8)
O Alert : Compos >entis " emp: +7oC. Anemi% (). 5%teri% (8). ,dema (8). C!anosis (8)
&!spnoe (8)
=od! 'eig$t: 0 -g" =od! lengt$: 14 %m
@ead Rig$t ,!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().
et e!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ()..
e%- !mp$ node enlargement (8)$ora6 Simetris usiormis. Retra%tion (8) epigastrial< inter%ostals" suprasternal.
@R: 110 *pm" reguler< murmur (8)
RR: 2 6Bi" regular" rales (8)
A*domen Soupel" Rapid turgor. normoperistalti%. iver" spleen and renal
unpalpa*le.
,6tremities Pulse 110 6Bi" regular" adeuate pBv" 'arm" CR D +U. =lood Pressure
1+0B90 mm$g
/enital >ale< 'it$in normal limit.A C$roni% #idne! &isease Stage 5G
P >anagement
E2 V 8 1 B5 nasal -anul
5G& &4; 4 gttB5 mi%ro
Spironola-ton 2624 mg
&iet pediasure mil- &iet 1994 --al +2 g protein
8/20/2019 Chronic Kidney Disease Stage IV
22/35
Planning
KS/ &oppler o -idne! and *ladder
,le%trolit %orre%tion result
CaBaB#BCl N 7.7B121B1.B9+ m,B
ull *lood %ount result
@*B@tBR=CBI=CBPlt N .7B1.9B2.+1610B9.4610+B+1610+
Iater =alan%e
5nput : &iet N 00 %% Eutput : EKP N 00 %% = N 5 8 E
5G& N 140 %% =A= N 0 N 80%%
otal N 740 %% 5I N 190 %% #?= N @S =C
otal N 790 %% N ++4 %%
A,g,$t@ 12
t4
"91S limp ()" nausea and vomit (8)"ever (8)
O Alert : Compos >entis " emp: +7oC. Anemi% (). 5%teri% (8). ,dema (8). C!anosis (8)
&!spnoe (8)
=od! 'eig$t: 0 -g" =od! lengt$: 14 %m
@ead Rig$t ,!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().
et e!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().. e%- !mp$ node enlargement (8)
$ora6 Simetris usiormis. Retra%tion (8) epigastrial< inter%ostals" suprasternal.
@R: 110 *pm" reguler< murmur (8)
RR: 2 6Bi" regular" rales (8)A*domen Soupel" Rapid turgor. normoperistalti%. iver" spleen and renal
unpalpa*le.,6tremities Pulse 110 6Bi" regular" adeuate pBv" 'arm" CR D +U. =lood Pressure
1+0B90 mm$g/enital >ale< 'it$in normal limit.
A C$roni% #idne! &isease Stage 5G
P >anagement
E2 V 8 1 B5 nasal -anul
5G& &4; 4 gttB5 mi%ro
Spironola-ton 2624 mg
&iet 1994 --al +2 g protein
Planning
KS/ &oppler o -idne! and *ladder
ranussion PRC + %%B-g** in 2 $ours
Iater =alan%e
8/20/2019 Chronic Kidney Disease Stage IV
23/35
5nput : &iet N 100 %% Eutput : EKP N +00 %% = N 5 8 E
5G& N 0 %% =A= N 0 N 00 %%
otal N 100 %% 5I N 200 %% #?= N @S =C
otal N 400 %% N 74 %%
A,g,$t@ 1t4 "91
S limp ()" nausea and vomit (8)"ever (8)O Alert : Compos >entis " emp: +7oC. Anemi% (). 5%teri% (8). ,dema (8). C!anosis (8)
&!spnoe (8)
=od! 'eig$t: 0 -g" =od! lengt$: 14 %m
@ead Rig$t ,!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().
et e!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().. e%- !mp$ node enlargement (8)
$ora6 Simetris usiormis. Retra%tion (8) epigastrial< inter%ostals" suprasternal.
@R: 110 *pm" reguler< murmur (8)
RR: 20 6Bi" regular" rales (8)A*domen Soupel" Rapid turgor. normoperistalti%. iver" spleen and renal
unpalpa*le.,6tremities Pulse 110 6Bi" regular" adeuate pBv" 'arm" CR D +U. =lood Pressure
120B0 mm$g/enital >ale< 'it$in normal limit.
A C$roni% #idne! &isease Stage 5G
P >anagement
5G& &4; 4 gttB5
Spironola-ton 2624 mg&iet 1994 --al +2 g protein
Planning
KS/ &oppler o -idne! and *ladder
ranussion PRC + %%B-g** in 2 $ours
A,g,$t@ 1=t4 "91
S limp ()" nausea and vomit (8)"ever (8)
O Alert : Compos >entis " emp: +7oC. Anemi% (). 5%teri% (8). ,dema (8). C!anosis (8)
&!spnoe (8)
=od! 'eig$t: 0 -g" =od! lengt$: 14 %m
@ead Rig$t ,!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().5%teri% s%lera (8). ig$t rele6 ().
et e!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ()..
e%- !mp$ node enlargement (8)$ora6 Simetris usiormis. Retra%tion (8) epigastrial< inter%ostals" suprasternal.
@R: 110 *pm" reguler< murmur (8)
8/20/2019 Chronic Kidney Disease Stage IV
24/35
RR: 2 6Bi" regular" rales (8)
A*domen Soupel" Rapid turgor. normoperistalti%. iver" spleen and renal
unpalpa*le.,6tremities Pulse 110 6Bi" regular" adeuate pBv" 'arm" CR D +U. =lood Pressure
120B0 mm$g
/enital >ale< 'it$in normal limit.A C$roni% #idne! &isease Stage 5G
P >anagement
5G& &4; 4 gttB5 mi-ro
Spironola-ton 2624 mg
&iet 1994 --al +2 g protein
Planning
KS/ &oppler o -idne! and *ladder
ranussion PRC + %%B-g** in 2 $ours
Repeat ele%trolit and A/&A
Iater =alan%e
5nput : &iet N 900 %% Eutput : EKP N 70 %% = N 5 8 E
5G& N +00 %% =A= N 200 %% N 200 %%
otal N 1200 %% 5I N 100 %% #?= N @S =C
otal N 1.000 %% N 74 200 %%
74 %%
&ipsti-
KroB=ilB#etB=loBProBitBeuB/luBS/Bp@
8B1B8B8B2B+B8B8B1.010B7.0
A,g,$t@ 1ale< 'it$in normal limit.
8/20/2019 Chronic Kidney Disease Stage IV
25/35
A C$roni% #idne! &isease Stage 5G
P >anagement
5G& &4; 4 gttB5
Spironola-ton 2624 mg
&iet 1900 --al +2 g protein
Planning
ranussion PRC + %%B-g** in 2 $ours
Iater =alan%e
5nput : &iet N 1+00 %% Eutput : EKP N 00 %% = N 5 8 E
5G& N 40 %% =A= N 0 N 8 240 %%
otal N +40 %% 5I N 200 %% #?= N @S =C
otal N 00 %% N 724 %%
A,g,$t@ "9t4 "91
S limp ()" nausea and vomit (8)"ever (8)
O Alert : Compos >entis " emp: +7.4"oC. Anemi% (). 5%teri% (8). ,dema (8). C!anosis (8)
&!spnoe (8)
=od! 'eig$t: 0 -g" =od! lengt$: 14 %m
@ead Rig$t ,!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ().
et e!e: Pupil diameter + mm. 5nerior palpe*ra %onHun%tiva pale ().
5%teri% s%lera (8). ig$t rele6 ()..
e%- !mp$ node enlargement (8)
$ora6 Simetris usiormis. Retra%tion (8) epigastrial< inter%ostals" suprasternal.
@R: 100 *pm" reguler< murmur (8)
RR: 20 6Bi" regular" rales (8)
A*domen Soupel" Rapid turgor. normoperistalti%. iver" spleen and renal
unpalpa*le.
,6tremities Pulse 100 6Bi" regular" adeuate pBv" 'arm" CR D +U. =lood Pressure
120B0 mm$g
/enital >ale< 'it$in normal limit.
A C$roni% #idne! &isease Stage 5G
P >anagement
5G& &4; 4 gttB5
Spironola-ton 2624 mg
&iet 1900 --al +2 g protein
Iater =alan%e
5nput : &iet N 900 %% Eutput : EKP N 70 %% = N 5 8 E
5G& N +00 %% =A= N 200 %% N 200 %%
otal N 1200 %% 5I N 100 %% #?= N @S =C
otal N 1.000 %% N 74 200 %%
74 %%
&ipsti-
8/20/2019 Chronic Kidney Disease Stage IV
26/35
KroB=ilB#etB=loBProBitBeuB/luBS/Bp@
8BB8B8BB8BB8B1.004B.4
8/20/2019 Chronic Kidney Disease Stage IV
27/35
Di$%,$$in
C$roni% -idne! disease" is a slo' progressive de%line o -idne! un%tion. 5tQs usuall! a
result o a %ompli%ation rom anot$er serious medi%al %ondition. Knli-e a%ute renal ailure"
'$i%$ $appens ui%-l! and suddenl!" %$roni% -idne! disease $appens graduall! T over period o
'ee-s" mont$s" or !ears T as t$e -idne! slo'l! stop 'or-ing" leading to end8stage renal disease
(,SR&).
$e -idne!s pla! t$ree ma!or roles :
Removing 'aste produ%t rom t$e *od!" -eeping to6in rom *uilding up in t$e
*loodstream
Produ%ing $ormones t$at %ontrol ot$er *od! un%tions" su%$ as regulating *lood
pressure produ%ting red *lood %ells
Regulating t$e levels o t$e minerals or ele%trol!tes (e.g." sodium" %al%ium" and
potassium) and luid in t$e *od!
$e most %ommon %auses o %$roni% -idne! disease in ort$ Ameri%a are dia*etes
mellitus (t!pe 1 or t!pe 2 dia*etes ) and $ig$ *lood pressure. $e most %ommon %ause o end
stage renal ailure 'orld'ide is 5gA nep$ropat$! (an inlammator! disease o -idne!s).
Et$er %ommon %auses o %$roni% renal ailure in%lude :
Re%urring p!elonep$ritis (-idne! ine%tion)
Pol!%!sti% -idne! disease (multiple %!sts in t$e -idne!s)
Autoimmune disorders su%$ as s!stemi% lupus er!t$emastosus
@ardening o t$e arteries" '$i%$ %an damage *lood vessels in t$e -idne!s
Krinar! tra%t *lo%-ages and relu6" due to reuent ine%tions" stones" or an
anatomi%al a*normalit! t$at $appened at *irt$
,6%essive use o medi%ations t$at are meta*oli3ed t$roug$ t$e -idne!
C$roni% -idne! disease %an *e present or man! !ears *eore !ou noti%e an! s!mptoms.
Patients 'it$ %$roni% -idne! disease (C#&) stage 18+ (glomerular i-tration rate +0
mBminB1.7+ m2) are reuentl! as!mptomati% < in termso possi*le WnegativeU s!mptoms related
simpl! to t$e loss o glomerular iltration rate (/R)" t$e! do not e6perien%e %lini%all! evident
distur*an%es in 'ater or ele%trol!te *alan%e or endo%rineBmeta*oli% derangements.
8/20/2019 Chronic Kidney Disease Stage IV
28/35
/enerall!" t$ese distur*an%es *e%ome %lini%all! maniest 'it$ C#& stages 84 (/R D +0
mBminB1.7+ m2 ). Patients 'it$ tu*ulointerstitial disease" %!sti% diseases" nep$roti% s!ndrome"
and ot$er %onditions asso%iated 'it$ Wpositive s!mptomsU (eg" pol!uria" $ematuria" edema) are
more li-el! to develop sign o disease at earlier stages. 5n patients 'e ound /R 2+"2
mBminB1.7+ m2. 5t s$o's %$roni% -idne! disease stage .
N 0.70 6 10 %m
.97mgBd
N 2+.2 mmBminB1.7+ m2
Anemia" '$i%$ in C#& develops primar! as a result o de%reased renal s!nt$esis o
er!t$ropoietin" maniests as atigue" redu%ed e6er%ise %apa%it!" impaired %ognitive and immune
un%tion" and redu%ed ualit! o lie. Anemia is also asso%iated 'it$ t$e development o
%ardiovas%ular disease" t$e ne' onset o $eart ailure" t$e development o more severe $eart
ailure" and in%reased %ardiovas%ular mortalit!. 5n patients 'e ound o la*oratorium result 'it$
@* 7.20 g;. 5t s$o's anemia.
!pi%al p$!si%al indings in persons 'it$ uremia are t$ose asso%iated 'it$ luid retention"
anemia" and a%idemia. Severe malnutrition %an %ontri*ute to mus%le 'asting" '$ile ele%trol!te
a*normalities ma! %ause mus%le %ramping" %ardia% arr$!t$mias" and mental status %$anges.
Et$er maniestations o uremia in end stage renal disease (,SR&)" man! o '$i%$ are more
li-el! in patients '$o are inadeuatel! dial!3ed" in%lude t$e ollo'ing :
Peri%arditis : %an *e %ompli%ated *! %ardia% tamponade" possi*l! resulting in deat$
,n%ep$alopat$! : %an progress to %oma and deat$
Perip$eral neuropat$!
Restless leg s!ndrome/astrointestinal s!mptoms : Anore6ia" nausea" vomiting" diarr$ea
S-in maniestation : &r! s-in" pruritus" e%%$!mosis
atigue" in%reased somnolen%e" ailure to t$rive
>alnutrition
,re%tile disun%tion" de%reased li*ido" amenorr$ea
8/20/2019 Chronic Kidney Disease Stage IV
29/35
Platelet disun%tion 'it$ tenden%! to *leed
reat t$ese pat$ologi% maniestations o %$roni% -idne! disease (C#&) as ollo's :
Anemia : I$en t$e $emoglo*in level is *elo' 10 gBd" treat 'it erit$ropoiesi8simulating
agents (,SAs) su%$ as epoetin ala or dar*epoetin ala
@!perp$osp$atemia : reat 'it$ dietar! p$osp$ate *inders and dietar! p$osp$ate restri%tion
Golume overload : reat 'it$ loop diureti% or ultrailtration
>eta*oli% a%idosis : reat 'it$ oral al-ali supplementation
Kremi% maniestation : reat 'i$ long T term renal repla%ement t$erap! ($emodial!sis"
peritoneal dial!sis" or renal transplantation)
Cardivas%ular %ompli%ation : reat as appropriate
/ro't$ ailure in %$ildren : reat 'it$ gro't$ $ormone
Corre%tion @iponatremiaast Corre%tion N (12089) 6 0 6 0. N 401. m, (inis$ed in $ours. Iit$ aCl +; N
401.B41+ N977%% N 10 gttB5 mi%roSlo' %orre%tion N (1+48124) 6 0 6 0. N 20 m,B
>aintanan%e N 2 8 m,B N 0 T 10 m,B
otal N +20 T 00 m,Iit$ 5G& &4; aCl 0.9; N +20B14 6 1000 N 2077 %% 144 gttB5 mi%ro" inis$ed in
1 $oursCorre%tion @ipo-alemia +0 m, in 90 %% &4;" inis$ in + $ours N 0 gttB5 mi-ro
1.7 m,B 'it$ 0.74 m,B-g==" +0 m, #Cl in 90 %% &4;" inis$ed in + $ours N 0 gttB5mi%ro
@!ponatremia is de%rease in serum a %on%entration D 1+ m,B %aused *! an e6%ess o
'ater relative to solute. Common %auses in%lude diureti% use" diarr$ea" $eart ailure" and renal
disease. Clini%al maniestation are primaril! neurologi% (due to an osmoti% s$it o 'ater into
*rain %ells %ausing edema)" espe%iall! in a%ute $!ponatremia" and in%lude $eada%$e" %onusion"
and stupor" sei3ures and %oma ma! o%%ur. S!mptoms o $!ponatremia in%lude nausea and
vomiting" $eada%$e" s$ort8term memor! loss" %onusion" let$arg!" loss o appetite" restlessness
and irrita*ilit!" mus%le 'ea-ness" spasms or %rumps" sei3ure" and de%reased %ons%iousness or
%oma. &iagnosis is *! measuring serum a. Serum and urine ele%trol!tes and osmolalit! $elp
determine t$e %ause. reatment involves restri%ting 'ater inta-e and promoting its loss" repla%ing
an! a dei%it" and %orre%ting t$e underl!ing %ause.
8/20/2019 Chronic Kidney Disease Stage IV
30/35
P&in%i'a) Ca,$e$ 5 H0'nat&emia
Me%4ani$m Categor! ,6amplesH0'6)emi%
40'nat&emia
De%&ea$e* T+
an* Na@ 3it4 a
&e)ati6e)0 g&eate&
*e%&ea$e in Na
/5 lossesX &iarr$ea
Gomiting
+rd8spa%e lossesX =urns
Pan%reatitis
Peritonitis
R$a*dom!ol!sis
Small8*o'el o*stru%tion
Renal losses &iureti%s
>ineralo%orti%oid dei%ien%!Esmoti% diuresis (glu%ose"
urea" mannitol )
Salt8losing nep$ropat$ies (eg"
interstitial nep$ritis"
medullar! %!sti% disease"
partial urinar! tra%t
o*stru%tion" pol!%!sti%
-idne! disease)E,6)emi%
40'nat&emia
In%&ea$e* T+
3it4 nea&n&ma)
tta) -*0 Na
&rugs &iureti%s" *ar*iturates"
%ar*ama3epine "
%$lorpropamide " %loi*rate "
opioids" tol*utamide "
vin%ristine
Possi*l! %!%lop$osp$amide "
SA5&s" o6!to%in&isorders Adrenal insui%ien%! as in
Addison disease
@!pot$!roidism
S!ndrome o inappropriate
A&@ se%retion
5n%reased inta-e o
luids
Primar! pol!dipsia
States t$at in%rease ,motional stress
8/20/2019 Chronic Kidney Disease Stage IV
31/35
nonosmoti% release
o A&@
Pain
Postoperative statesH0'e&6)emi%
40'nat&emia
In%&ea$e* tta)
-*0 Na 3it4 a
&e)ati6e)0 g&eate&
in%&ea$e in T+
,6trarenal disorders Cirr$osis
@eart ailure
Renal disorders A%ute -idne! d!sun%tion
C$roni% -idne! disease
ep$roti% s!ndromeGI an* !&*$'a%e )$$e$ %a,$e 40'nat&emia i5 &e')a%ement 5),i*$
a&e 40'tni% %m'a&e* 3it4 )$$e$.
T+ tta) -*0 3ate&.
5n patients" natrium %on%entration is 9 m,B. 5t is severe $!ponatremia (serum a D 109
m,B). reatment is more %ontroversial '$en neurologi% s!mptoms (eg" %onusion" let$arg!"
sei3ure" %oma) are present. $e de*ate primar! %on%ern t$e pa%e and degree o $!ponatremia
%orre%tion. @!pertoni% (+;) saline (%ontaining 41+ m, aB) ma! *e used" *ut onl! 'it$
reuent ( 2 to $) ele%trol!te determination. or patients 'it$ sei3ures or %oma" 100 mB$
ma! *e administrated over to $ in amounts sui%ient to raise t$e serum a to m,B.
$is amount (in m,) ma! *e %al%ulated using t$e a dei%it ormula as
(&esired C$ange in a) 6 =I " '$ere =I is 0. 6 *od! 'eig$t in -g in men and 0.4 6 *od! 'eig$t in -g in 'omen.
@iponatremia %orre%tion in patients :
ast Corre%tion N (12089) 6 0 6 0. N 401. m, (inis$ed in $ours. Iit$ aCl +; N
401.B41+ N977%% N 10 gttB5 mi%roSlo' %orre%tion N (1+48124) 6 0 6 0. N 20 m,B
>aintanan%e N 2 8 m,B N 0 T 10 m,Botal N +20 T 00 m,
Iit$ 5G& &4; aCl 0.9; N +20B14 6 1000 N 2077 %% 144 gttB5 mi%ro" inis$ed in
1 $ours
#alium %on%entration in patient is 1.7 m,B. $e normal potassium level is +.484.0
m,B. o' potassium is deined as a potassium level *elo' +.4 m,B. o' potassium levels
($!po-alemia)" %an %ause 'ea-ness as %ellular pro%esses are impaired. o' potassium %an o%%ur
8/20/2019 Chronic Kidney Disease Stage IV
32/35
or man! reasons. Kse o 'ater pills (diureti%s)" diarr$ea" and %$roni% la6ative a*use are t$e most
%ommon %auses o lo' potassium levels .1
Et$er %auses o $!po-alemia in%lude : 1
Ki*ne0 )$$e$
Certain -idne! disorder su%$ as renal tu*ular a%idosis (or e6ample" %$roni% -idne! ailure and
a%ute -idne! disease)>agnesium dei%ien%!eu-emia
Cus$ingQs disease (and ot$er adrenal disorder)
L$$ 5 'ta$$i,m t4&,g4 $tma%4 an* inte$tine$
Gomiting
,nemas or e6%essive la6ative use&iarr$ea
Ater ileostom! operation
E55e%t 5 me*i%ineIater pills (diureti%s)
>edi%ined used or ast$ma or emp$!sema (*eta8adrenergi% agonist t!pe o drugs su%$ as
*ron%$odilators" steroids" or t$eop$!lline)
Aminogl!%osides ( a t!pe o anti*ioti% used or treating %ertain serious ine%tions)
S4i5ting 5 'ta$$i,m int an* ,t 5 %e))$ %an )3e& t4e %n%ent&atin 5 'ta$$i,m
mea$,&e* in t4e -)*
Kse o insulin
Certain meta*oli% states (su%$ as al-alosis)
De%&ea$e* 5* intae & ma)n,t&itin
Anore6ia=ulimia
=ariatri% surger!
Al%o$olism
@!po%alemia %orre%tion:
D 2.4 m,B : 0.74 m,B-g *od! 'eig$t 'it$ ratio &4; 1 : + and inis$ed in + $.
2.4 T + m,B : 0.4 m, B-g *od! 'eig$t 'it$ ratio &4; 1 : +" and inis$ed in 2 $.+.4 m,B : 0.24 m,B-g *od! 'eig$t 'it$ ratio &4; 1 : +" and inis$ed in 1 $.
5n patients potassium %on%entration is 1.7 m,B 'it$ %al%ulated potassium %orre%tion :1.7 m,B 'it$ 0.74 m,B-g==" +0 m, #Cl in 90 %% &4;" inis$ed in + $ours N 0 gttB5 mi%ro
8/20/2019 Chronic Kidney Disease Stage IV
33/35
8/20/2019 Chronic Kidney Disease Stage IV
34/35
Cn%),$in$
A *o! age 14 !ears suering rom stage %$roni% -idne! disease stage 'it$ /R 2+.2
mBminB1.7+ m2.
8/20/2019 Chronic Kidney Disease Stage IV
35/35
REFERENCE
Su'itra #. Pen!a-it /inHal #roni-. 5n: Sudo!o AI" Seti!o$adi =" Al'i 5" # >S Setiati S.
200. =u-u AHar 5lmu Pen!a-it &alam. ,d 5G. ?a-arta: Pusat Pener*itan &epartemen 5lmu
Pen!a-it &alam< 200. P 470847+.Cores$ ?" Astor =C" /reene " ,lno!an /" eve! AS. Prevalen%e o C$roni% #idne! &isease
And &e%reased #idne! un%tion 5n $e Adult KS Population: $ird ational @ealt$ and
utrition ,6amination Surve!. Am ? #idne! &is. 200+/" @o P" ,mmett " et al. C$roni% renal insui%ien%! in %$ildren: t$e 2001Annual Report o t$e APRCS. Pediatr Ne&hrol . Aug 200+" @a'le! C>" >%&onald SP" et al. Predi%tors o renal re%over! in Australian and
e' Oealand end8stage renal ailure patients treated 'it$ peritoneal dial!sis. Perit Dial +nt .
>ar8Apr 2007